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ABSTRACT
Objectives: To determine what factors are associated
with the time people take to consult with symptoms of
lung cancer, with a focus on those from rural and socially
deprived areas.
Methods: A cross-sectional quantitative interview survey
was performed of 360 patients with newly diagnosed
primary lung cancer in three Scottish hospitals (two in
Glasgow, one in NE Scotland). Supplementary data were
obtained from medical case notes. The main outcome
measures were the number of days from (1) the date
participant defined first symptom until date of presenta-
tion to a medical practitioner; and (2) the date of earliest
symptom from a symptom checklist (derived from clinical
guidelines) until date of presentation to a medical
practitioner.
Results: 179 participants (50%) had symptoms for more
than 14 weeks before presenting to a medical practitioner
(median 99 days; interquartile range 31–381). 270
participants (75%) had unrecognised symptoms of lung
cancer. There were no significant differences in time
taken to consult with symptoms of lung cancer between
rural and/or deprived participants compared with urban
and/or affluent participants. Factors independently asso-
ciated with increased time before consulting about
symptoms were living alone, a history of chronic
obstructive pulmonary disease (COPD) and longer pack
years of smoking. Haemoptysis, new onset of shortness
of breath, cough and loss of appetite were significantly
associated with earlier consulting, as were a history of
chest infection and renal failure.
Conclusion: For many people with lung cancer,
regardless of location and socioeconomic status, the time
between symptom onset and consultation was long
enough to plausibly affect prognosis. Long-term smokers,
those with COPD and/or those living alone are at particular
risk of taking longer to consult with symptoms of lung
cancer and practitioners should be alert to this.
Only 7% of patients with lung cancer in Scotland
are alive 5 years after diagnosis;1 a similar picture
exists in England and Wales.2 Five-year lung cancer
survival rates in the UK are well below the average
rates of Europe and America.2 So too are surgical
resection rates; only 11% of patients in the UK
receive curative surgery compared with 17% in
Europe and 21% in North America.1 Differences in
collection and presentation of data may account
for some of this variation, but the ‘‘consistency of
international comparisons’’ suggests that other
factors are also at play.3 Stage at diagnosis is one
such factor. Most patients with lung cancer in the
UK are diagnosed at a late stage when curative
surgery is no longer an option.4 5 Late presentation
of symptoms to a medical practitioner is recognised
as being part of the problem.4 6–8
Late presentation of cancer symptoms is a
common and well-documented event.8–11 Decis-
ions on when to seek medical help are often bound
up in a complex mix of individual psychosocial
factors.12–14 The effects of previous public and
professional neglect of lung cancer may also still
endure. A recent qualitative study reported late
presentation of lung cancer symptoms as a
universal feature.8 Participants, regardless of their
disease stage, failed to recognise the seriousness of
their symptoms and reported noticeable changes in
health long before seeking medical help. This and
other lung cancer research15 challenges the general
belief that lung cancer is asymptomatic until
advanced.
Geographical variation in lung cancer survival
also exists within the UK. Research into cancer
inequalities in Scotland has shown that people
from rural and deprived areas have poorer lung
cancer survival than people from urban and
affluent areas.16–19 There is no evidence that
healthcare providers in Scotland differentially
delay referral and/or treatment for lung and other
cancers in these groups.20–22 Differences in attitude
to consulting a clinician with symptoms of cancer
between people in rural and urban areas have been
reported,23 but whether those in rural and deprived
communities wait longer before seeking medical
help is unknown. A delay of even a few months in
seeking medical help is believed to have a sig-
nificant influence on stage at diagnosis and
prognosis.24 Reducing the time taken to consult
with symptoms of lung cancer in those more likely
to postpone seeking medical help may help
improve survival.25 However, as the reasons for
late presentation are not fully understood, a greater
appreciation of the process that occurs before first
contact with a medical practitioner is required.
This study aimed to explore this process and to
determine what patient factors are associated with
the time taken to consult with symptoms of lung
cancer, and whether those from rural and/or
deprived areas wait longer than those from urban
and/or affluent areas before seeking medical help.
METHODS
Consecutive patients with primary lung cancer
were identified by specialist nurses at three
Scottish hospitals (one in north-east Scotland and
two in Glasgow) early after diagnosis between
April 2004 and January 2006. Both locations treat
patients across the spectrum of rurality and
deprivation.
Lung cancer
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Indicators of deprivation were assigned to cases according to
their postcode at the time of diagnosis. Carstairs deprivation
scores were calculated from 2001 census data26 at the output
area level (the lowest level geography used to produce statistical
output from the census) and grouped into population quintiles.
Rural and urban status was allocated according to quintiles of
travelling distance from a participant’s postcode to the nearest
cancer centre; this measure was previously found to be
associated with diagnosis of lung cancer at a later stage and
poorer early survival.16 18 Because of difficulties in answering
survey questions, patients who had impaired consciousness,
dementia or psychosis were excluded from the study. Patients
considered by clinicians to be too unwell to be approached were
also excluded. Participants agreeable to the study received an
information sheet and allowed their details to be passed to the
study researcher. Contact was made and the study was
explained in full before obtaining signed consent. Data were
then collected using a quantitative interview survey (see below).
In addition, dates of consultations, referral and first hospital
contact, and data on co-morbidities (previous cancer, chest and
cardiovascular disease, gastrointestinal and hepatic disease,
musculoskeletal problems and psychiatric problems) were
abstracted from GP and hospital case notes.
Quantitative interview survey
Participants were asked about their initial symptoms and the
dates they were first noticed. Two definitions of first symptom
were used—participant-defined and health professional-
defined—using a checklist of symptoms compiled from Cancer
Research UK lung cancer symptoms27 and SIGN guidelines.1
Further data included knowledge of lung cancer symptoms;
previous consulting behaviour; exposure to risk factors; family
history of cancer; and perception of self-risk of cancer.
Individual socioeconomic data (including education, employ-
ment and home ownership) were collected to test deprivation
validity at the individual patient level. Additional variables
shown to be associated with illness behaviour such as living
alone, having someone with whom to discuss symptoms and
relationship with their GP were also included.
Outcome measures
The main outcomes were (1) the number of days from date of
first symptom defined by the participant until date of
presentation of symptoms to a medical practitioner and (2) the
number of days from date of earliest symptom from the
symptom checklist until date of presentation of symptoms to a
medical practitioner.
Study power
A total sample size of 400 was projected to give 80% power to
detect an absolute difference of 14% (50% versus 36%) in two
equal group comparisons of patients waiting .12 weeks before
presenting to a medical practitioner at the 5% significance level.
If numbers in one group fell to 150, the study would have a
similar power to detect a difference of 16%.
Statistical analysis
Statistical analyses were conducted using SPSS for Windows
Version 15. Univariate analyses (x2 tests, Pearson correlation
and t tests) were performed to examine the association of the
independent variables with each outcome variable. Time to
consultation had a skewed distribution and a log transforma-
tion was required before analysis. The results were converted
back to geometric means (transformed 95% confidence inter-
vals, CI) for presentation of the univariate results. To determine
which participant factors had an independent association with
each outcome, multiple linear regression analyses were per-
formed. The factors age, sex, distance to cancer centre, Carstairs
deprivation scores and area (north-east Scotland or Glasgow)
were initially forced into the model. Other factors were entered
into the initial model if they had shown a significant univariate
association at p(0.20. A backward stepwise removal process
selected predictor variables if p.0.10. In order to make the
interpretation of the regression models easier, the antilog of
each regression coefficient and its 95% CI are presented. For
categorical factors the resultant values can be interpreted as the
number of times longer that a particular group took to consult
their GP compared with the reference group. For continuous
Table 1 Participant demographic and socioeconomic
characteristics (n = 360)
Characteristic No (%)
Age group (years)
(49 18 (5)
50–59 74 (21)
60–69 114 (32)
70–79 122 (34)
>80 32 (9)
Sex
Male 210 (58)
Female 150 (42)
Ethnicity
White 359 (.99)
Pakistani 1 (,1)
Education
No qualifications 153 (43)
Higher/A level 110 (31)
HNC/HND 10 (3)
Professional/technical qualifications 54 (15)
University degree 15 (4)
GSVQ/SVQ 18 (5)
Smoking
Ex-smoker 235 (65)
Smoker at time of interview 110 (31)
Never smoker 15 (4)
Area
North-east Scotland 190 (53)
Glasgow 170 (47)
Home ownership
Own home 218 (60)
Rent home 132 (37)
Other 10 (3)
Travelling distance to nearest cancer centre (miles)
,5 187 (52)
5–,10 51 (14)
10–,15 14 (4)
15–,20 17 (5)
20–,25 5 (1)
25–,30 9 (3)
>30 77 (21)
Travelling distance to GP (miles)
(1 120 (33)
1–,3 163 (45)
3–,5 56 (15)
5–,7 11 (4)
7–,11 10 (3)
Lung cancer
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factors the coefficients refer to the proportionate change in time
taken to consult for each unit increase in the continuous factor.
RESULTS
Over the 92-week study period, 835 people with primary lung
cancer were identified; 154 people were ineligible, most of
whom were deemed too ill by clinicians to be approached about
the study. A further 23 whose eligibility status was not
confirmed had also to be excluded. A total of 658 were eligible
for the study and 620 were approached; 113 of these refused. Of
the remaining 507, 96 withdrew before giving full consent, 24
died before an interview could take place and contact was lost
with 26. A total of 361 participants were recruited and
completed quantitative interview surveys (all were face-to-face
apart from two which were conducted by telephone). One
participant reported first presenting with symptoms of lung
cancer 10 years previously and was excluded from the rest of
the analyses as an outlier. Three hundred and forty-six (96%) of
both hospital and GP case notes were reviewed. Comparing
dates of first consultation reported by participants with GP case
note recorded dates, 32% (n = 102) were within 1 week, 36%
(n = 114) between 8 and 30 days and 32% (n = 100) more than
1 month. No evidence of reporting bias between affluent,
deprived, rural and urban groups was found.
Participant characteristics
The sample (n = 360) consisted of 58% men and 42% women.
The characteristics of the participants are shown in table 1. Their
median age was 68 years (interquartile range (IQR) 59–74),
ranging from 37 to 87 years. Sixty-two (17%) lived in the least
deprived areas (Carstairs quintile 1) and 128 (36%) lived in the
most deprived areas (Carstairs quintile 5). The median travelling
distance to a cancer centre was 4.5 miles (IQR 2.2–22.0), range
0.6–227 miles, and 77 (21%) lived 30 miles or more from their
nearest cancer centre. Three hundred and thirty-five (78%)
lived within 3 miles of their GP. Only 4% of the participants
had never smoked and 201 (56%) of smokers and ex-smokers
reported not perceiving themselves to be at risk of lung
cancer before their diagnosis despite being aware of the risks
of smoking. Two hundred and seventy (75%) reported having
no knowledge of lung cancer symptoms and 171 (51%)
reported not having believed that their first symptom(s) was
serious.
Time to presentation of symptoms
The median time from participant-defined first symptoms to
consultation with a medical practitioner was 21 days (IQR 7–56).
The median time from earliest reported checklist symptoms until
consultation was 99 days (IQR 31–381).
Recognition of symptoms
Most participants, even those who described themselves as
having no first symptoms, reported additional symptoms in
response to the symptom checklist, suggesting that these
symptoms were possibly ignored or not recognised as relevant,
salient or indicative of serious illness (table 2).
Effects of deprivation and rurality
On univariate analysis, neither deprivation nor rurality was
significantly associated with time to consultation. This was
confirmed after adjustment for other significant variables in
both models (tables 3 and 4). Of the related variables, increasing
travel distance to general practices (p = 0.079) and social contact
with GPs away from the surgery (p = 0.049), both of which are
more common in rural areas, were associated with increasing
time between first participant-defined symptom and consulta-
tion on univariate analysis, but not when adjusted for other
factors (table 3). People who were currently or had previously
been in paid employment consulted sooner after their earliest
checklist symptom than those who had never been in paid
employment (p = 0.037), but the difference was no longer
statistically significant after adjusting for other variables
(p = 0.092, table 4).
A wide variety of factors were associated univariately with
time to consultation. However, different factors were indepen-
dently related to the time between first checklist symptom and
presentation and the time between first participant-defined
symptom and presentation (tables 3 and 4).
Table 2 Earliest checklist symptoms experienced, participant-defined first symptoms and checklist
symptoms at time of presentation to a medical practitioner (n = 360)
Symptoms
Earliest checklist
symptom(s) experienced
No (%)
Participant-defined
first symptom(s)
No (%)
Checklist symptom(s)
at time of
presentation
No (%)
Cough 70 (19) 117 (32) 218 (61)
Shortness of breath 76 (21) 81 (22) 211 (59)
Coughing up phlegm 49 (14) 27 (7) 177 (49)
Tiredness/fatigue/lethargy 57 (16) 51 (14) 118 (33)
More short of breath than usual 41 (11) 11 (3) 126 (35)
Loss of weight 71 (20) 27 (7) 124 (34)
Loss of appetite 57 (16) 23 (6) 111 (31)
Pain in chest/shoulders/back related to
breathing or coughing
49 (14) 53 (15) 108 (30)
Hoarse voice 38 (10) 8 (2) 81 (22)
Change in a cough 18 (5) 3 (1) 68 (19)
Haemoptysis 17 (5) 44 (12) 61 (17)
Difficulty swallowing 12 (3) 5 (1) 23 (6)
Swelling of the face or neck 11 (3) 11 (3) 21 (6)
‘‘No symptoms’’ (eg, incidental finding) – 27 (7) 4 (1)
Median (IQR) number of symptoms experienced 1 (1–2) 2 (1–2) 4 (2–5)
Lung cancer
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The shorter time between participant-defined first symp-
tom and presentation to a medical practitioner showed little
relationship with symptoms. On the other hand, it was
predicted by previous illness, being shorter in those with
cardiovascular disease but longer in those with previous
upper gastrointestinal disease. People who regularly con-
sulted their GP before their diagnosis consulted sooner with
lung cancer symptoms, and those who stated they would
complain to a higher authority if unhappy with their general
practice took longer (although this was not an independent
predictor).
For the longer time between earliest checklist symptom and
presentation, more symptoms characteristics were significantly
associated with time to consultation (table 4). Of social factors,
living alone was the independent factor most strongly
associated with time to consultation. Related variables (eg,
having someone to talk to about symptoms or being prompted
to consult by others) were not significant independent
predictors. Some co-morbidities (previous chest infection or
renal failure) were independently associated with a shorter time
to consultation, while a history of chronic obstructive
pulmonary disease (COPD) and increasing pack-years of
smoking were independently associated with increased time to
consultation.
DISCUSSION
We found no substantial differences in the time taken to present
with symptoms of lung cancer between people living in rural,
urban, affluent or deprived areas but, for all groups, these times
were long. Most participants had unrecognised symptoms of
lung cancer and half had experienced them for more than
14 weeks before presenting to a medical practitioner, indicating
that symptoms were either ignored or not understood to be
potentially serious even after the diagnosis of cancer had been
made.
This study is the largest of its kind to collect such extensive
data on reported lung cancer symptoms and symptom duration
before consultation that we have been able to identify.28 This
has allowed us to quantify the importance of symptoms, co-
morbidities and social factors as determinants of this lag time. A
limitation is that it relied on self-reporting by participants so
may have been subject to recall bias although, where we could
check recall against case note records (for example, consultation
dates), we found it to be reasonably good. We need to
acknowledge that reports of some behaviours are not just
affected by recall but by people’s natural desire to avoid blaming
themselves for waiting with serious symptoms or to avoid
facing the stigma of a smoking-related disease.29 Also, first
symptoms of lung cancer if non-specific can easily be dismissed.
We were also aware that recruiting patients with lung cancer
would be difficult because of their rapid clinical deterioration
and high early death rate, so monitored all losses at the various
stages of recruitment. This process confirmed that a notable
proportion died early or were otherwise medically unfit to take
part, and our data may not be representative of these groups.
Our findings add weight to qualitative research that shows
symptoms are experienced for several months before consulta-
tion with a medical practitioner,8 even though it is generally
thought to be asymptomatic until it is advanced. This contrasts
with five previous quantitative studies which reported median
times to consultation of 1 month or less.28 30 In the National
Survey of NHS patients,30 time before consultation was only
reported for the minority of patients who presented directly to
hospital either with incidental findings or as emergencies. This
and the four smaller studies28 did not use symptoms checklists
and their findings are in line with the shorter lag time we found
from patient-defined first symptoms: our research shows that
patients experience unrecognised symptoms for many preceding
weeks. This study is also in agreement with other research
reporting on the most common first clinical features of lung
cancer.15
That smoking was associated with increased time to
consultation might be viewed as counterintuitive, given that
the relationship between smoking and lung cancer is so well
known. On the other hand, we found that smokers said they
did not perceive themselves to be at risk—this ‘‘unrealistic
optimism’’ has been reported in other studies of risk
perception,31 32 nor did we find any evidence that high
perceived risk was associated with consulting sooner (if
anything, we found the reverse). It could be that smokers
were more tolerant of symptoms, regarding them as ‘‘normal’’
for smokers.
The most important social factor associated with time to
consult in our study was living alone, which has been found
previously in patients with breast cancer and heart disease.28 33 34
This may be because co-habitees notice symptoms and
‘‘sanction help-seeking behaviour’’. Previous research has con-
centrated on the latter,11 but our findings suggest the former
may be more important. We have confirmed the findings of
recent qualitative research which suggested that co-morbidities
may be important in causing patients to hold off before
consulting,8 and quantified their importance. In particular,
people with COPD took twice as long to consult with
symptoms. More encouragingly, we also found that some co-
morbidities were associated with reduced time to consultation;
those who had previously experienced a chest infection
requiring hospital treatment consulted in half the time of
others. This suggests that people who have previously been
alerted to certain symptoms consult with them more quickly,
providing encouragement that effective intervention may be
possible.
The implications of our findings are twofold. First, lung
cancer is almost always symptomatic, usually for several
months before consultation. The median time from the earliest
symptom to consultation is more than the estimated doubling
time of lung cancer and plausibly long enough to affect stage at
diagnosis and prognosis.35 It follows that, if people with
symptoms consulted earlier and were investigated appropri-
ately, there is potential to improve survival from lung cancer.
Second, most symptoms go unnoticed for several weeks, so
earlier consultation will only occur if people are alert to
symptoms and know to consult with them. Achieving this will
not, however, be easy. Key processes include symptom
recognition, motivation by people to have their symptoms
investigated and stimulating triggers to consultation. A lung
cancer awareness campaign may be of merit. However, it is not
yet known if this can be achieved to an extent that could affect
survival, so further research is needed. Further research is also
needed to understand the particular issues relating to presenta-
tion in those who present in poor condition or who rapidly
deteriorate.
Practitioners, in particular GPs, should be aware of the
potential to diagnose lung cancer earlier. This includes
recognising and acting on chest symptoms, particularly in
high-risk groups, and being aware that patients may not have
understood the potential significance of their new chest
symptoms, especially if they have a history of COPD, live
alone and have smoked for a long time.
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